CD274 and neuroblastoma: The use of anti-PD-L1 treatment for NB, including high-risk NB, and its links to the TME were discussed in this review [50], while other studies reported that an extraterminal domain bromodomain inhibitor (JQ1) and anti-PD-L1 combination treatment may be useful for treating high-risk NB [27].